Financials
- Market Capitalization 25.6 B
- Employee 721
- Founded 2014
- CEO Matt Gline
- Website www.roivant.com
- Headquarter Bermuda
- FIGI N/A
- Industry Biotecnologia
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-51.3
Rapporto prezzo/fatturato
2 326.88
Related tickers
| # | Nome | Prezzo | 24h % | 7d % | 1M % | 1Y % | Valore di Mercato | Ultimi 7 Giorni | |
|---|---|---|---|---|---|---|---|---|---|
| 367 | RVMD Revolution Medicines, Inc. - Common Stock | 189.76 USD | +0.87% | -8.63% | -6.75% | +242.53% | 40.67 B USD | ||
| 434 | ALNY Alnylam Pharmaceuticals, Inc. - Common Stock | 232.68 USD | +3.63% | +6.56% | -6.99% | -48.99% | 31.13 B USD | ||
| 499 | RPRX Royalty Pharma plc - Class A Ordinary Shares | 56.93 USD | +1.28% | -0.30% | -2.95% | +52.79% | 25.42 B USD | ||
| 524 | UTHR United Therapeutics Corporation - Common Stock | 549.16 USD | +3.07% | +1.60% | +8.38% | +25.51% | 23.55 B USD |